FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106706172> ?p ?o ?g. }

• W2106706172 endingPage "1033" @default.
• W2106706172 startingPage "1033" @default.
• W2106706172 abstract "Prednisolone or pentoxifylline is recommended for severe alcoholic hepatitis, a life-threatening disease. The benefit of their combination is unknown.To determine whether the addition of pentoxifylline to prednisolone is more effective than prednisolone alone.Multicenter, randomized, double-blind clinical trial conducted between December 2007 and March 2010 in 1 Belgian and 23 French hospitals of 270 patients aged 18 to 70 years who were heavy drinkers with severe biopsy-proven alcoholic hepatitis, as indicated by recent onset of jaundice in the prior 3 months and a Maddrey score of at least 32. Duration of follow-up was 6 months. The last included patient completed the study in October 2010. None of the patients were lost to follow-up for the main outcome.Patients were randomly assigned to receive either a combination of 40 mg of prednisolone once a day and 400 mg of pentoxifylline 3 times a day (n=133) for 28 days, or 40 mg of prednisolone and matching placebo (n=137) for 28 days.Six-month survival, with secondary end points of development of hepatorenal syndrome and response to therapy based on the Lille model, which defines treatment nonresponders after 7 days of initiation of treatment.In intention-to-treat analysis, 6-month survival was not different in the pentoxifylline-prednisolone and placebo-prednisolone groups (69.9% [95% CI, 62.1%-77.7%] vs 69.2% [95% CI; 61.4%-76.9%], P = .91), corresponding to 40 vs 42 deaths, respectively. In multivariable analysis, only the Lille model and the Model for End-Stage Liver Disease score were independently associated with 6-month survival. At 7 days, response to therapy assessed by the Lille model was not significantly different between the 2 groups (Lille model score, 0.41 [95% CI, 0.36-0.46] vs 0.40 [95% CI, 0.35-0.45], P = .80). The probability of being a responder was not different in both groups (62.6% [95% CI, 53.9%-71.3%] vs 61.9% [95% CI, 53.7%-70.3%], P = .91). The cumulative incidence of hepatorenal syndrome at 6 months was not significantly different in the pentoxifylline-prednisolone and the placebo-prednisolone groups (8.4% [95% CI, 4.8%-14.8%] vs 15.3% [95% CI, 10.3%-22.7%], P = .07).In patients with alcoholic hepatitis, 4-week treatment with pentoxifylline and prednisolone, compared with prednisolone alone, did not result in improved 6-month survival. The study may have been underpowered to detect a significant difference in incidence of hepatorenal syndrome, which was less frequent in the group receiving pentoxifylline.clinicaltrials.gov Identifier: NCT01214226." @default.
• W2106706172 created "2016-06-24" @default.
• W2106706172 creator A5003479866 @default.
• W2106706172 creator A5003944446 @default.
• W2106706172 creator A5004361418 @default.
• W2106706172 creator A5005205127 @default.
• W2106706172 creator A5014621165 @default.
• W2106706172 creator A5015975130 @default.
• W2106706172 creator A5016419093 @default.
• W2106706172 creator A5038859257 @default.
• W2106706172 creator A5044773924 @default.
• W2106706172 creator A5046999467 @default.
• W2106706172 creator A5050044901 @default.
• W2106706172 creator A5051068310 @default.
• W2106706172 creator A5052064056 @default.
• W2106706172 creator A5058740520 @default.
• W2106706172 creator A5065731342 @default.
• W2106706172 creator A5067483186 @default.
• W2106706172 creator A5070860490 @default.
• W2106706172 creator A5073789519 @default.
• W2106706172 creator A5075141136 @default.
• W2106706172 creator A5077112002 @default.
• W2106706172 creator A5088338447 @default.
• W2106706172 creator A5091756794 @default.
• W2106706172 date "2013-09-11" @default.
• W2106706172 modified "2023-10-15" @default.
• W2106706172 title "Prednisolone With vs Without Pentoxifylline and Survival of Patients With Severe Alcoholic Hepatitis" @default.
• W2106706172 cites W1570622790 @default.
• W2106706172 cites W1889183644 @default.
• W2106706172 cites W1974609452 @default.
• W2106706172 cites W1981248031 @default.
• W2106706172 cites W1998645206 @default.
• W2106706172 cites W2001288327 @default.
• W2106706172 cites W2002221121 @default.
• W2106706172 cites W2007258272 @default.
• W2106706172 cites W2007334837 @default.
• W2106706172 cites W2045765874 @default.
• W2106706172 cites W2047732107 @default.
• W2106706172 cites W2060637877 @default.
• W2106706172 cites W2061831231 @default.
• W2106706172 cites W2073048831 @default.
• W2106706172 cites W2073140442 @default.
• W2106706172 cites W2085964948 @default.
• W2106706172 cites W2101592596 @default.
• W2106706172 cites W2104802633 @default.
• W2106706172 cites W2140396673 @default.
• W2106706172 cites W2141922524 @default.
• W2106706172 cites W2142873961 @default.
• W2106706172 cites W2149449252 @default.
• W2106706172 cites W2151825728 @default.
• W2106706172 cites W2153359097 @default.
• W2106706172 doi "https://doi.org/10.1001/jama.2013.276300" @default.
• W2106706172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24026598" @default.
• W2106706172 hasPublicationYear "2013" @default.
• W2106706172 type Work @default.
• W2106706172 sameAs 2106706172 @default.
• W2106706172 citedByCount "185" @default.
• W2106706172 countsByYear W21067061722013 @default.
• W2106706172 countsByYear W21067061722014 @default.
• W2106706172 countsByYear W21067061722015 @default.
• W2106706172 countsByYear W21067061722016 @default.
• W2106706172 countsByYear W21067061722017 @default.
• W2106706172 countsByYear W21067061722018 @default.
• W2106706172 countsByYear W21067061722019 @default.
• W2106706172 countsByYear W21067061722020 @default.
• W2106706172 countsByYear W21067061722021 @default.
• W2106706172 countsByYear W21067061722022 @default.
• W2106706172 countsByYear W21067061722023 @default.
• W2106706172 crossrefType "journal-article" @default.
• W2106706172 hasAuthorship W2106706172A5003479866 @default.
• W2106706172 hasAuthorship W2106706172A5003944446 @default.
• W2106706172 hasAuthorship W2106706172A5004361418 @default.
• W2106706172 hasAuthorship W2106706172A5005205127 @default.
• W2106706172 hasAuthorship W2106706172A5014621165 @default.
• W2106706172 hasAuthorship W2106706172A5015975130 @default.
• W2106706172 hasAuthorship W2106706172A5016419093 @default.
• W2106706172 hasAuthorship W2106706172A5038859257 @default.
• W2106706172 hasAuthorship W2106706172A5044773924 @default.
• W2106706172 hasAuthorship W2106706172A5046999467 @default.
• W2106706172 hasAuthorship W2106706172A5050044901 @default.
• W2106706172 hasAuthorship W2106706172A5051068310 @default.
• W2106706172 hasAuthorship W2106706172A5052064056 @default.
• W2106706172 hasAuthorship W2106706172A5058740520 @default.
• W2106706172 hasAuthorship W2106706172A5065731342 @default.
• W2106706172 hasAuthorship W2106706172A5067483186 @default.
• W2106706172 hasAuthorship W2106706172A5070860490 @default.
• W2106706172 hasAuthorship W2106706172A5073789519 @default.
• W2106706172 hasAuthorship W2106706172A5075141136 @default.
• W2106706172 hasAuthorship W2106706172A5077112002 @default.
• W2106706172 hasAuthorship W2106706172A5088338447 @default.
• W2106706172 hasAuthorship W2106706172A5091756794 @default.
• W2106706172 hasConcept C126322002 @default.
• W2106706172 hasConcept C141071460 @default.
• W2106706172 hasConcept C142724271 @default.
• W2106706172 hasConcept C204787440 @default.
• W2106706172 hasConcept C27081682 @default.
• W2106706172 hasConcept C2776029263 @default.
• W2106706172 hasConcept C2776715498 @default.

• next